Comment on Udell et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. Diabetes Care 2015;38:696-705.

Subjects

Subjects :

Female
Humans
Male
Adamantane analogs & derivatives
Cardiovascular Diseases epidemiology
Diabetes Mellitus, Type 2 drug therapy
Diabetes Mellitus, Type 2 epidemiology
Diabetic Nephropathies drug therapy
Dipeptides therapeutic use
Renal Insufficiency drug therapy

Details

Language :

English

ISSN :

1935-5548

Volume :

38

Issue :

6

Database :

MEDLINE

Journal :

Diabetes care

Publication Type :

Editorial & Opinion

Accession number :

25998303

Full Text :

https://doi.org/10.2337/dc15-0006